Search Results for 'dsm'

LanzaTech, Novozymes, Amyris, DSM, Enerkem, POET, BASF, Genomatica and Avantium among early Hot 50 voting leaders

LanzaTech, Novozymes, Amyris, DSM, Enerkem, POET, BASF, Genomatica and Avantium among early Hot 50 voting leaders

December 5, 2017 |

In Florida, LanzaTech, Novozymes, Amyris, DSM, Enerkem, POET, BASF, Genomatica and Avantium have taken the lead in early voting in the 50 Hottest Companies in the Advanced Bioeconomy ballot. The Digest released the early-voting totals from Subscriber Voting — which do not yet include Invited International Selector votes. This week’s summary includes phioto and other bonus votes which […]

Read More

Amyris’ Sweet-‘N-High: Biotech pioneer sells farnesene plant to DSM, focuses on next-gen sweetener

Amyris’ Sweet-‘N-High: Biotech pioneer sells farnesene plant to DSM, focuses on next-gen sweetener

November 20, 2017 |

The nine month and Q3 2017 results are in for Amyris, and there’s reason for the long-suffering shareholder to take some near-Christmas cheer. YTD revenue is up more than 1/3 and product revenue has more than doubled. Guidance for year-end revenues was upped. The company has found a new deep-pocketed champion in DSM. But there […]

Read More

Breaking the Bottleneck – POET-DSM achieves cellulosic biofuel breakthrough

Breaking the Bottleneck – POET-DSM achieves cellulosic biofuel breakthrough

November 3, 2017 |

It’s hard to believe the Digest was reporting on POET’s grand opening of its Project LIBERTY facility back in 2014, then its reaching of production goals earlier this year in April with yields of about 70 gallons of cellulosic per ton of corn stover, near its goal of 72 gallons, and now here we are […]

Read More

Amyris announces second product development tie up with Royal DSM

Amyris announces second product development tie up with Royal DSM

September 26, 2017 |

In California, Amyris, Inc. announced that it has entered into a product development and production agreement for Vitamin A with Koninklijke DSM N.V. This marks the second such agreement between the two parties. DSM is partnering with Amyris to fund the development of the technology to produce Vitamin A on a cost-advantaged basis utilizing Amyris’s […]

Read More

Amyris enters first production development and production agreement with DSM

Amyris enters first production development and production agreement with DSM

July 17, 2017 |

In California, Amyris announce it has entered into its first product development and production agreement with Koninklijke DSM N.V. (Royal DSM), the global science-based company active in health, nutrition and materials, to develop a food and nutrition molecule for which DSM is a major market provider. As part of the previously announced equity investment DSM […]

Read More

First $47 million investment tranche led by Royal DSM into Amyris closed

First $47 million investment tranche led by Royal DSM into Amyris closed

May 15, 2017 |

In California, Amyris, Inc. announced the closing of the first tranche of up to $95 million in planned equity financing that the company previously announced on May 8, 2017. The first tranche was approximately $47 million and was led by Koninklijke DSM N.V. (Royal DSM) with participation by qualified institutional buyers and accredited investors, including […]

Read More

Amyris says “double the revenue” in sight with Nenter Vitamin E Partnership as DSM Vitamin A partnership unveiled

Amyris says “double the revenue” in sight with Nenter Vitamin E Partnership as DSM Vitamin A partnership unveiled

May 11, 2017 |

In California, Amyris said it expects revenue related to its Vitamin E partnership with Nenter to more than double based on the current success of the program. During 2016, the company shipped approximately $9 million of farnesene to Nenter for conversion to Vitamin E and expects 2017 shipments to Nenter to be about $20 million. […]

Read More

DSM invests $25 million in Amyris

DSM invests $25 million in Amyris

May 8, 2017 |

In California, Amyris, Inc. the industrial bioscience company, and Koninklijke DSM N.V., the global science-based company active in health, nutrition and materials, announced that they have agreed for DSM to make an equity investment in Amyris. At the same time, the companies will enter into a development cooperation focused on products for the global health […]

Read More

Strategic Intent: The Digest’s 2017 Multi-Slide Guide to DSM in the advanced bioeconomy

Strategic Intent: The Digest’s 2017 Multi-Slide Guide to DSM in the advanced bioeconomy

May 8, 2017 |

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences, DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such […]

Read More

DSM invests in Amyris

DSM invests in Amyris

May 8, 2017 |

In California, DSM led a round of investors that will put up to $95 million in equity financing into Amyris via a registered direct offering of convertible preferred stock, and private placements of convertible preferred stock and warrants. Amyris is in the process of reducing its debt by approximately $75 million. DSM has agreed to […]

Read More